Peptide Research Database

Access 7,487 peer-reviewed studies, clinical trials, and research papers on peptides. Filter by key research, study type, compound, and category. Direct links to full PubMed entries for comprehensive, evidence-based exploration.

Other
PMID: 42981240
2026 Nov 04

Investigating GLP-1 sourcing preferences on social media and motivations for use: Survey with choice-based conjoint (CBC) exercise.

This study found overall, our findings identify influential attributes of GLP-1 social media ads (i.e., branding and visual display of products) and suggests greater support is needed for online moderation efforts to prevent high-risk purchasing activity and increase safe access to GLP-1s for those with medical needs.

Haupt MR, Weiss SM, Calac AJ, Salazar S, Larsen MZ, Mackey TK

The growing use of glucagon-like peptide 1 (GLP-1) drugs such as Ozempic for weight loss interventions has led to increased concerns about inappropriate use, supply shortages, and high-risk sourcing. However, little is known about the influence of online marketing strategies on purchasing preferences for GLP-1 products. This study uses a survey with a Choice-Based Conjoint (CBC) exercise to assess features of social media posts that are most influential for intent to purchase GLP-1 products and identify motivations for use. Participants were recruited based on current use of GLP-1 drugs, previous use, or considering use (n = 242). Utility scores from the conjoint analysis quantified the influence of tested features. Conjoint findings showed greater preference for posts that feature branded semaglutide (e.g., Wegovy)(15.38, SD = 45.29), display products in packaging (47.49, SD = 46.72), have accredited digital pharmacies as the seller (25.16, SD = 47.31) (e.g., Amazon Pharmacy), include medical endorsements for diabetes treatment (13.16, SD = 49.04), and offer a free consultation (13.18, SD = 32.00). Analysis was conducted on survey questions measuring GLP-1 purchasing channels and motivations for use. Over half of participants (51.7%) reported that social media content influenced their perceptions of GLP-1 drugs and 45.8% (n = 65) of GLP-1 users reported purchasing product from high-risk sources (i.e., personal network or individual sellers online). Exploratory analysis shows a possible association between self-reported high-risk sourcing and reliance on GLP-1s for medical conditions. Overall, our findings identify influential attributes of GLP-1 social media ads (i.e., branding and visual display of products) and suggests greater support is needed for online moderation efforts to prevent high-risk purchasing activity and increase safe access to GLP-1s for those with medical needs.

Other
PMID: 42980414
2026 Nov 04

Structure-Guided Remodeling of Multi-Substrate Binding Pocket in Nicotinamide Mononucleotide Adenylyltransferase for Efficient NAD+ Synthesis.

This study found collectively, this study provides a transferable framework for engineering complex multisubstrate enzymes by integrating structural dynamics with process-scale validation.

Wei D, Li L, Cui Y, Huang Y, Zou S, Xue Y, Zheng Y

The rational engineering of enzymes that coordinate multiple substrates within a confined active site remains a major challenge in biocatalysis. Here, we present a structure-guided dual-cluster engineering strategy that exploits low epistatic coupling among conserved residues to independently tune electronic and geometric active-site features while avoiding trade-offs. This approach was validated through re-engineering Methanothermobacter thermautotrophicus nicotinamide mononucleotide adenylyltransferase. The optimal triple mutant MT3 (V6C/Q10E/P11T) showed a 5.1-fold increase in catalytic efficiency (kcat/Km) over wild type. Molecular dynamics simulations revealed that the mutations synergistically compact the substrate-binding pocket, reduce the catalytic distance by 1.4 Å, and reshape local electrostatics to stabilize a near-attack conformation, thereby lowering the reaction barrier. In a 30-L bioreactor, MT3 achieved 85.3% conversion and a titer of 112.5 g L-1 NAD+ within 8 h, underscoring its industrial potential. Collectively, this study provides a transferable framework for engineering complex multisubstrate enzymes by integrating structural dynamics with process-scale validation.

Journal of agricultural and food chemistry
Review
Notable
PMID: 42998653
2026 Nov 04

Neuropeptide Systems in Substance use Disorders: Therapeutic evidence and molecular mechanisms.

In a research review, future progress will depend on integrating peptide engineering, targeted delivery platforms, biomarker-guided patient selection, and well-designed clinical trials to expand effective.

Nejhaddadgar N, Imani NS, Isazadehfar K, Jamali Z

Substance use disorders remain a major global health challenge, with limited pharmacological options and no approved medications for several addictive substances. Peptide-based therapeutics have emerged as promising candidates because they regulate neural circuits involved in reward, motivation, stress, and energy homeostasis. This narrative review summarizes current evidence for therapeutic peptides in substance use disorders, examines their molecular mechanisms, evaluates advances in peptide engineering and delivery technologies, and discusses future translational and precision-medicine strategies. A structured narrative review was conducted according to the Scale for the Assessment of Narrative Review Articles recommendations. PubMed/MEDLINE, Scopus, Web of Science, Embase, Google Scholar, and ClinicalTrials.gov were searched (January 2000-July 2026) using controlled vocabulary and free-text terms related to therapeutic peptides, receptors, delivery systems, and substance use disorders. Fifteen peptide and neuropeptide systems were identified. Glucagon-like peptide-1 receptor agonists currently show the strongest clinical evidence, particularly for alcohol use disorder, while findings for nicotine, cocaine, and opioid use disorders remain limited. Oxytocin, orexin receptor antagonists, ghrelin, and dynorphin-related therapies demonstrate encouraging early findings. In contrast, corticotropin-releasing factor type-1 and neurokinin-1 receptor antagonists show target engagement without consistent clinical benefit. Several systems, including neuropeptide Y, galanin, pituitary adenylate cyclase-activating polypeptide, cocaine- and amphetamine-regulated transcript, melanocortins, and enkephalins, remain largely preclinical. Advances in peptide engineering, nanotechnology, blood-brain barrier delivery, intranasal administration, and long-acting formulations may overcome pharmacokinetic limitations. Peptide therapeutics represent a rapidly evolving strategy for addiction treatment. Future progress will depend on integrating peptide engineering, targeted delivery platforms, biomarker-guided patient selection, and well-designed clinical trials to expand effective.

Neuropeptides
Clinical Trial
Highly Cited
PMID: 42979856
2026 Nov 04

Tirzepatide for the treatment of obstructive sleep apnea: from apnea-hypopnea index reduction to cardiometabolic risk mitigation-a narrative review.

In a randomized trial, long-term durability of effect after discontinuation, generalizability beyond the SURMOUNT-OSA-eligible population, OSA-specific economic analysis, and head-to-head comparisons against CPAP remain the principal unsettled questions requiring dedicated long-term studies before firm clinical recommendations can be made.

Mesfin-Bireda S, Hillman Urek K

Obstructive sleep apnea (OSA) is a chronic respiratory disorder with nocturnal oxygen desaturation that is often associated with multisystemic sequelae such as hypertension, cardiovascular diseases, and increased morbidity and mortality. Obesity has been proposed as a modifiable risk factor; hence, the recent shift in focus to investigating anti-obesity medications for the management of OSA. Tirzepatide is the first U.S. FDA-approved pharmacotherapy for the treatment of moderate-to-severe OSA in adults with obesity to be utilized in combination with low caloric intake and physical activity, given its prior success in managing type 2 diabetes (T2D) and obesity. This narrative review evaluates tirzepatide and the SURMOUNT-OSA trial program as the key contemporary anchors for the pharmacological treatment of OSA in adults with concurrent obesity. Because the randomized evidence base currently comprises a single pivotal trial program, the review centers on SURMOUNT-OSA and its prespecified endpoints along with post hoc analyses, supplemented by observational, modeling, and mechanistic studies. In the SURMOUNT-OSA program, tirzepatide produced randomized, placebo-controlled reductions in the apnea-hypopnea index, sleep apnea-specific hypoxic burden, body weight, and systemic inflammation. The program was designed around respiratory and metabolic endpoints rather than clinical events, so it cannot support conclusions about mortality, cardiovascular, or renal outcomes. Favorable signals for those events, including all-cause mortality, major adverse kidney events, and major adverse cardiovascular events, come only from nonrandomized observational cohorts and are best regarded as directional and exploratory rather than definitive.  Tirzepatide may help frame OSA as a multifactorial and partially metabolically treatable disease and may represent a clinically meaningful expansion of treatment options alongside, rather than as a replacement for, established mechanical and procedural therapies. The available evidence is anchored in a single phase 3 trial program and limited by short follow-up and the absence of definitive comparative and long-term outcome data. Long-term durability of effect after discontinuation, generalizability beyond the SURMOUNT-OSA-eligible population, OSA-specific economic analysis, and head-to-head comparisons against CPAP remain the principal unsettled questions requiring dedicated long-term studies before firm clinical recommendations can be made.

Multidisciplinary respiratory medicine
Animal Study
Notable
PMID: 42994383
2026 Nov 04

Tensile stress enhances osteogenic differentiation of rat bone marrow mesenchymal stem cells in a PC12 co-culture model through soluble-factor signaling.

In a cell culture study, applying mechanical tension to bone-forming stem cells enhanced their differentiation when grown with nerve cells, resulting in increased mineralization and bone marker expression. The effect was mediated by nerve growth factors and signaling molecules exchanged between the two cell types.

Li S, Liu J, Lv Y

Mechanical stimulation and neural regulation are critical for bone repair, yet how neural cells modulate mesenchymal stem cell (MSC) osteogenic differentiation under mechanical cues remains unclear. MSCs and pheochromocytoma cell 12 (PC12) cells were indirectly co-cultured in a Transwell system, with tensile stress (TS) applied exclusively to the MSCs. MSC osteogenic differentiation, Wnt/β-catenin signaling-related molecules, and neurotrophic factors were evaluated. IWR-1 was used to assess the involvement of Wnt/β-catenin signaling. Conditioned medium (CM) from TS-treated MSC/PC12 co-cultures was applied to PC12 to assess proliferation, neuronal-like differentiation, and paracrine activity. CM from these treated PC12 was then applied to MSCs to assess its effects on osteogenic differentiation. TS enhanced alkaline phosphatase (ALP) activity, matrix mineralization, and osteogenic marker expression in MSCs co-cultured with PC12, accompanied by increased Wnt3a and β-catenin expression; these effects were attenuated by IWR-1. TS also increased nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) expression in MSCs and their levels in co-culture CM. CM from TS-treated MSC/PC12 co-cultures stimulated PC12 proliferation, neurite outgrowth, neuronal-like differentiation, and secretion of vasoactive intestinal peptide (VIP) and calcitonin gene-related peptide (CGRP). In turn, CM collected from PC12 after exposure to TS-treated MSC/PC12 co-culture CM further enhanced MSC osteogenic differentiation. TS enhanced MSC osteogenic differentiation in the PC12 co-culture model and was accompanied by soluble-factor-associated responses between MSCs and PC12. The changes in Wnt3a and β-catenin expression, together with the inhibitory effect of IWR-1, suggest an association between Wnt/β-catenin signaling-related responses and MSC osteogenic differentiation.

Tissue & cell
Other
PMID: 42911641
2026 Nov 04

Progesterone feedback effects on LH pulse and surge secretion in ovariectomized Bos taurus, Bos indicus, and crossbred heifers.

This study found in conclusion, P4 suppressed LH pulse frequency without altering surge magnitude. Reveals that progesterone suppresses LH pulse frequency without altering the GnRH-induced LH surge in ovariectomized heifers and, regardless of progesterone environment, Bos indicus heifers have lower LH release and fewer hypothalamic kisspeptin and dynorphin brain cells.

West S, Silva LOE, Garza V, Sustaita-Monroe J, King L, Bynum S, Ecord E, Perry G, Sartori R, Cardoso RC

In brief: Progesterone is a key regulator of hypothalamic-pituitary function, and its regulatory effects appear to differ between Bos indicus and Bos taurus cattle. This study reveals that progesterone suppresses LH pulse frequency without altering the GnRH-induced LH surge in ovariectomized heifers and, regardless of progesterone environment, Bos indicus heifers have lower LH release and fewer hypothalamic kisspeptin and dynorphin neurons. Abstract: This study evaluated the effects of progesterone (P4) on LH pulse and surge secretion, and hypothalamic neuroendocrine differences between Bos indicus, Bos taurus, and crossbred heifers. Ovariectomized Brahman (n = 8), Hereford (n = 6), and Braford (F1; n = 7) heifers received estradiol (E2) implants to maintain low E2 concentrations. On day -5, each heifer from the three genetic groups (Gen) was exposed to high P4 (HP4; two controlled internal drug releases [CIDRs] for 5 days), decreasing P4 (DP4; sequential CIDR removal from day -1.5), and no P4 (NoP4) environments, creating a 3 × 3 crossover factorial design. Serial blood samples were collected for 8 hr on day -0.5 (Pulse period) and for 6.5 hr on day 0 (Surge period) following a gonadotropin-releasing hormone (GnRH) challenge (100 µg gonadorelin-acetate intramuscularly) to evaluate LH secretion. Subsequently, hypothalamic tissue was collected for dual-label immunofluorescence of kisspeptin and dynorphin in the arcuate nucleus. Circulating P4 differed among environments (p < 0.01) but was not affected by Gen (p = 0.98), with no interaction. LH pulse frequency was reduced under HP4 and increased under DP4 compared with NoP4 (2.7 ± 0.4, 6.7 ± 0.5, and 5.0 ± 0.6 pulses/8 hr; p < 0.01), with no Gen effect (p = 0.48). However, Bos indicus heifers exhibited lower LH pulse amplitude and peak than Bos taurus and crossbred (p < 0.01). P4 environment did not affect GnRH-induced LH surge (p = 0.96), but Bos taurus had greater surge than crossbred and Bos indicus (p < 0.01). Additionally, Bos indicus had fewer kisspeptin- and dynorphin-immunopositive neurons in the arcuate nucleus. In conclusion, P4 suppressed LH pulse frequency without altering surge magnitude. Regardless of P4 environment, Bos indicus heifers exhibited reduced LH secretion and fewer kisspeptin/dynorphin neurons than Bos taurus.

Reproduction (Cambridge, England)
Meta-Analysis
Landmark Study
DOI
2026-11-04

Falls, fractures, lean mass and age with GLP-1receptor agonists and tirzepatide: meta-analysis of 162 placebo-controlled trials andage-subgroup data for adults aged 75 years orolder

In a combined analysis of multiple studies, within SELECT (semaglutide 2.4 mg, n = 17,604), the fracture RR rose across age bands from 0.47 (0.25–0.91) at.

Ohe K.

Abstract Background. Weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and tirzepatide includes loss of lean mass, raising concern about falls and fractures in older adults. Whether harm increases with participant age, and whether benefit persists at 75 years or older, has not been examined systematically. Methods. We extracted serious adverse events coded as "Fall", any fracture, and hip/femur fracture from all placebo-controlled, parallel-group randomised trials of GLP-1 RAs or tirzepatide in adults (treatment ≥ 12 weeks) with results posted on ClinicalTrials.gov (searched 31 October 2026), and searched PubMed (1 November 2026) for placebo-controlled trials reporting lean mass by dual-energy X-ray absorptiometry (DXA). Risk ratios (RR) and mean differences (MD) were pooled by random-effects models (REML, Hartung-Knapp), and effect modification by trial mean age was tested by meta-regression. Post hoc, we extracted results by participant age from FDA review documents and published subgroup analyses, and pooled placebo-controlled trials reporting 6-minute walk distance (6MWD) and bone-turnover markers. Results. In 162 trials (83,571 participants on GLP-1 RA or tirzepatide, 62,962 on placebo; trial mean ages up to 74 years), serious falls (k = 30; RR 0.91, 95% CI 0.77–1.07), any serious fracture (k = 76; RR 0.90, 0.80–1.01) and hip/femur fracture (k = 22; RR 1.04, 0.80–1.36) were not increased, and meta-regression showed no association with trial mean age (falls: RR per 10 years 0.92, 0.55–1.54; p = 0.75). Lean mass fell by 2.76 kg more than with placebo (9 trials, mean age 29–53 years; −3.78 to − 1.74), and by 4.12 kg in the four semaglutide or tirzepatide trials. Within SELECT (semaglutide 2.4 mg, n = 17,604), the fracture RR rose across age bands from 0.47 (0.25–0.91) at

Other
PMID: 42979829
2026 Nov 04

The molecular basis of GshT substrate binding reveals how Streptococcus pneumoniae acquires the antioxidant glutathione.

This study found together, our data demonstrate that a lock-and-key charge complementarity drives the GshT-glutathione interaction.

du Toit SE, Pace PE, De Cordovez P, Göbl C, Dickerhof N

Glutathione is synthesised across all kingdoms of life, but certain bacteria, including the major pathogen Streptococcus pneumoniae, import host glutathione instead. Glutathione import is known to involve the substrate-binding protein GshT, but the molecular basis underlying glutathione scavenging by pneumococcal GshT remains incompletely understood. We used isothermal titration calorimetry to demonstrate that pneumococcal GshT binds glutathione with low micromolar affinity. Thermal shift assays with glutathione derivatives demonstrated that two adequately spaced carboxylates in glutathione are essential for binding. Monitoring NMR chemical shift perturbations of mutated GshT variants upon glutathione addition revealed that two conserved positively charged residues lining the ligand-binding pocket determine the ability to bind glutathione. Mutagenesis of these residues in S. pneumoniae abolished GSH uptake, impaired growth and lowered oxidant tolerance. Together, our data demonstrate that a lock-and-key charge complementarity drives the GshT-glutathione interaction. Our findings provide insights into pathogen survival mechanisms that may inform strategies to combat infectious disease.

The FEBS journal
Review
Notable
PMID: 42978208
2026 Nov 03

Next-generation incretin therapeutics for polyendocrine metabolic ovarian syndrome: navigating current pipeline and clinical considerations.

In a review of incretin-based therapies for polycystic ovary syndrome, newer dual and triple hormone medications showed greater metabolic benefits than single-agent GLP-1 drugs, including larger weight loss and improved insulin resistance. However, their effects on reproductive function, long-term safety, and whether benefits persist after stopping treatment remain unclear.

Ozgen Saydam B, Yıldız BO

Polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), is a complex metabolic-reproductive disorder managed with lifestyle interventions, metformin, and symptom-directed therapies. Incretin-based therapies offer substantial metabolic benefits, but their reproductive efficacy, durability, and phenotypic safety remain incompletely defined. This narrative review examines the therapeutic evolution from single glucagon-like peptide-1 (GLP-1) receptor agonists to dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonism with tirzepatide and triple GIP/GLP-1/glucagon receptor agonism with retatrutide. A structured PubMed search of studies published from January 2023 to October 2026 was supplemented by ClinicalTrials.gov and reference-list screening. Evidence was evaluated across metabolic, hormonal, and reproductive outcomes. Single GLP-1 receptor agonists, particularly semaglutide, improve weight, adiposity, and insulin resistance, with emerging evidence of reproductive benefits. Multi-incretin therapies may provide greater reductions in body weight, visceral and ectopic fat, and insulin resistance. However, PMOS-specific reproductive evidence remains limited. Whether reproductive benefits are independent of weight loss, persist after treatment withdrawal, or differ across PMOS phenotypes is uncertain. Phenotype-stratified randomized trials with standardized reproductive, metabolic, cardiovascular and safety endpoints are needed to determine whether multi-incretins provide durable benefits beyond weight control while maintaining reproductive safety and accessibility.

Expert opinion on pharmacotherapy
Other
PMID: 42977490
2026 Nov 03

Recommendations for the use of semaglutide for the management of obesity in children and young people in England: expert consensus statements using a Delphi-like process.

Lim DBN, Hawton K, Dias RP, Aswani N, Steele C, Sachdev P, Peacock A, Robertson S, Marshall A, Tang W, Skae M, Idkowiak J, Van Boxel E, Brandt-Varma A, Hamilton-Shield J, Davis N

Archives of disease in childhood